- Home
- TOI vs NERV Comparison
TOI vs NERV Comparison
Compare TOI & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOI
- NERV
- Stock Information
- Founded
- TOI 2007
- NERV 2007
- Country
- TOI United States
- NERV United States
- Employees
- TOI N/A
- NERV N/A
- Industry
- TOI Medical/Nursing Services
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- TOI Health Care
- NERV Health Care
- Exchange
- TOI Nasdaq
- NERV Nasdaq
- Market Cap
- TOI 20.1M
- NERV 18.3M
- IPO Year
- TOI N/A
- NERV 2014
- Fundamental
- Price
- TOI $0.25
- NERV $2.32
- Analyst Decision
- TOI Strong Buy
- NERV Hold
- Analyst Count
- TOI 1
- NERV 1
- Target Price
- TOI $2.50
- NERV $5.00
- AVG Volume (30 Days)
- TOI 187.1K
- NERV 25.6K
- Earning Date
- TOI 11-13-2024
- NERV 11-05-2024
- Dividend Yield
- TOI N/A
- NERV N/A
- EPS Growth
- TOI N/A
- NERV N/A
- EPS
- TOI N/A
- NERV N/A
- Revenue
- TOI $361,067,000.00
- NERV N/A
- Revenue This Year
- TOI $29.17
- NERV N/A
- Revenue Next Year
- TOI $16.43
- NERV N/A
- P/E Ratio
- TOI N/A
- NERV N/A
- Revenue Growth
- TOI 23.31
- NERV N/A
- 52 Week Low
- TOI $0.23
- NERV $2.26
- 52 Week High
- TOI $2.50
- NERV $13.49
- Technical
- Relative Strength Index (RSI)
- TOI 39.10
- NERV 39.53
- Support Level
- TOI $0.25
- NERV $2.26
- Resistance Level
- TOI $0.30
- NERV $2.43
- Average True Range (ATR)
- TOI 0.04
- NERV 0.13
- MACD
- TOI -0.00
- NERV -0.01
- Stochastic Oscillator
- TOI 19.31
- NERV 8.77
About TOI The Oncology Institute Inc.
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.